Holen Sie sich die Stockscreener-App
0.00
100.00%
-131.87
Schlusskurs vom Vortag:
$131.87
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$14.05B
Einnahmen:
$612.78M
Nettoeinkommen (Verlust:
$-86.37M
KGV:
0.00
EPS:
-0.87
Netto-Cashflow:
$-62.91M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$131.98
52-Wochen-Spanne:
$0.00
$131.98
Intra Cellular Therapies Inc Stock (ITCI) Company Profile
Firmenname
Intra Cellular Therapies Inc
Sektor
Telefon
(646) 440-9333
Adresse
135 ROUTE 202/206, BEDMINSTER, NY
Vergleichen Sie ITCI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ITCI
Intra Cellular Therapies Inc
|
0.00 | 14.05B | 612.78M | -86.37M | -62.91M | -0.87 |
|
ZTS
Zoetis Inc
|
161.57 | 73.88B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.17 | 48.17B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.50 | 47.59B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.19 | 17.28B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
308.89 | 13.78B | 2.76B | 1.11B | 898.10M | 22.77 |
Intra Cellular Therapies Inc Stock (ITCI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-24 | Herabstufung | Mizuho | Outperform → Neutral |
| 2025-01-31 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2024-09-06 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-01-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-12-11 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-08-22 | Herabstufung | Goldman | Buy → Neutral |
| 2022-07-07 | Eingeleitet | Mizuho | Buy |
| 2022-06-14 | Eingeleitet | UBS | Buy |
| 2022-04-22 | Eingeleitet | Piper Sandler | Neutral |
| 2022-02-16 | Eingeleitet | Goldman | Buy |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2020-12-15 | Eingeleitet | BofA Securities | Buy |
| 2020-12-10 | Eingeleitet | Goldman | Buy |
| 2020-02-20 | Eingeleitet | Evercore ISI | Outperform |
| 2020-01-31 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-12-24 | Bestätigt | Canaccord Genuity | Buy |
| 2019-08-12 | Eingeleitet | Jefferies | Buy |
| 2018-02-26 | Eingeleitet | JP Morgan | Overweight |
| 2018-02-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-12-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-11-08 | Hochstufung | SunTrust | Hold → Buy |
| 2017-09-07 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2017-08-30 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2017-08-24 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-08-23 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2017-05-02 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2017-05-02 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2017-05-01 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-12-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-09-29 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-09-29 | Herabstufung | SunTrust | Buy → Neutral |
Alle ansehen
Intra Cellular Therapies Inc Aktie (ITCI) Neueste Nachrichten
J&J to complete acquisition of Intra-Cellular Therapies - Medical Buyer
JnJ closes Intra-Cellular Therapies acquisition - Medical Dialogues
JNJ forecasts 2025 profit dilution from Intra-Cellular deal, sets closing date - MSN
Demystifying Intra-Cellular Therapies: Insights From 6 Analyst Reviews - Benzinga
Intra-Cellular Therapies acquired by Johnson & Johnson for $14.6 billion - Investing.com
Intra-Cellular Therapies Completes Merger with Johnson & Johnson - TipRanks
Johnson & Johnson acquires Intra-Cellular Therapies By Investing.com - Investing.com South Africa
Stock Of The Day: Will Johnson & Johnson Rally? The Sell-Off May Have Ended - Benzinga
Johnson & Johnson Acquires Intra-Cellular Therapies - citybiz
Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership - BioSpace
Johnson & Johnson Completes Intra-Cellular Therapies Purchase - MarketScreener
JNJ Completes Acquisition Of Intra-Cellular Therapies - Nasdaq
Johnson & Johnson acquires Intra-Cellular Therapies - Investing.com
Johnson & Johnson completes Intra-Cellular Therapies acquisition, sees dilution - TipRanks
Johnson & Johnson (JNJ) Closes Intra-Cellular Therapies, Inc. (ITCI) Acquisition - StreetInsider
Johnson & Johnson Expands Its Horizon With Intra-Cellular Therapies Deal - Finimize
Johnson & Johnson Expects Lower Earnings Impact From Intra-Cellular Therapies Acquisition - MarketScreener
Johnson & Johnson Set To Complete Acquisition Of Intra-Cellular Therapies By April 2, 2025 - Nasdaq
Johnson & Johnson to finalize Intra-Cellular buyout By Investing.com - Investing.com Canada
Johnson & Johnson to finalize Intra-Cellular buyout - Investing.com
Johnson & Johnson Intra-Cellular acquisition to accelerate FY25 sales by 0.8% - TipRanks
Johnson & Johnson (JNJ) Sets April 2nd as Expected Closing Date for Intra-Cellular Acquisition - StreetInsider
Johnson & Johnson Announces Expected Closing Date for Intra-Cellular Acquisition - The Joplin Globe
(ITCI) On The My Stocks Page - news.stocktradersdaily.com
Intra-Cellular Therapies Stock Hits All-Time High of $131.79 By Investing.com - Investing.com South Africa
Intra-Cellular Therapies Shareholders Approve Johnson & Johnson Merger - Investing.com
Intra-Cellular Therapies Shareholders Approve Johnson & Johnson Merger By Investing.com - Investing.com Australia
Beam Therapeutics (BEAM) Down 21.4% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Intra-Cellular Therapies Stock Hits All-Time High of $131.79 - Investing.com
Intra-Cellular Therapies: These Are 5 Critical Challenges Threatening Its Expansion Plans! - Smartkarma
Intra-Cellular Therapies announces proxy statement supplement By Investing.com - Investing.com South Africa
Intra-Cellular Therapies announces proxy statement supplement - Investing.com
Intra-Cellular Therapies stockholder filed lawsuit against co, board in NY Supreme Court - Marketscreener.com
Intra-Cellular Therapies Stock Hits All-Time High of $131.47 By Investing.com - Investing.com UK
Intra-Cellular Therapies (ITCI): Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance
US Bancorp DE Sells 4,330 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Defense World
Scrip M&A Podcast: Looking At M&A Activity As Q1 Nears A Close - Scrip
Intra-Cellular Therapies (NASDAQ:ITCI) Now Covered by StockNews.com - Defense World
Intra-Cellular Therapies Stock Hits All-Time High of $131.37 By Investing.com - Investing.com Australia
Intra-Cellular Therapies Stock Hits All-Time High of $131.37 - Investing.com
Jones Financial Companies Lllp Acquires 2,750 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Defense World
Charles Schwab Investment Management Inc. Increases Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Defense World
Long Term Trading Analysis for (ITCI) - Stock Traders Daily
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Purchased by Bank of New York Mellon Corp - Defense World
Lisanti Capital Growth LLC Increases Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular deal, Axsome settlement drive neurological index recovery - BioWorld Online
Intra-Cellular Therapies, Inc. to Host Earnings Call - ACCESS Newswire
J&J to stop studies of depression drug due to low effectiveness - Reuters.com
Johnson & Johnson: No More Tears, Just Gains In Intra-Cellular Acquisition - Seeking Alpha
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives Average Recommendation of “Hold” from Brokerages - Defense World
Intra-Cellular Therapies (NASDAQ:ITCI) Coverage Initiated at StockNews.com - Defense World
Finanzdaten der Intra Cellular Therapies Inc-Aktie (ITCI)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.61%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):